Price$2.24+0.14 (+6.67%)
02:15 PM07:45 PM
News · 26 weeks360%
2026-04-192026-10-11
Mix2390d
- SEC Filings9(39%)
- Other6(26%)
- Insider5(22%)
- Earnings2(9%)
- Analyst1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Beyond Air Inc.4 - Beyond Air, Inc. (0001641631) (Issuer)
- SECSEC Form 8-K filed by Beyond Air Inc.8-K - Beyond Air, Inc. (0001641631) (Filer)
- PRBeyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last year Performance reflects continued adoption for first-generation LungFit PH; second-generation system remains under FDA review Reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 GARDEN CITY, N.Y., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced preliminary, unaudited
- INSIDERLarge owner Lin Yi-Chien bought $56,590 worth of shares (20,393 units at $2.77), increasing direct ownership by 16% to 145,393 units (SEC Form 4)4 - Beyond Air, Inc. (0001641631) (Issuer)
- INSIDERNew insider Lin Yi-Chien claimed ownership of 125,000 shares (SEC Form 3)3 - Beyond Air, Inc. (0001641631) (Issuer)
- SECBeyond Air Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update8-K - Beyond Air, Inc. (0001641631) (Filer)
- PRBeyond Air to Participate in the 2026 Cantor Global Healthcare ConferenceGARDEN CITY, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that its management team will participate in the 2026 Cantor Global Healthcare Conference, which is being held at the Waldorf Astoria New York, New York on September 9-11, 2026. Fireside Chat Details:Date: Thursday, September 10thTime: 3:55 PM EDT Webcast Link: A live webcast of the fireside chat will be available on the Events section of the Company’s website, https://www.beyondair.net/news-events/events. Following the live presentation, a repla
- ANALYSTLake Street initiated coverage on Beyond Air with a new price targetLake Street initiated coverage of Beyond Air with a rating of Buy and set a new price target of $10.00
- PRBeyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)GARDEN CITY, N.Y., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to LungFit GO for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD). The Breakthrough Device Designation underscores the significant unmet need in NTM-PD and builds upon clinical data generated with LungFit GO within this patient population. Results from the Company's pilot study, which were published
- PRBeyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone PaymentsBeyond Air to receive shares representing 19.99% of Univo's issued and outstanding share capital upon closing Beyond Air eligible to receive up to $32.5 million in development and commercial milestone payments GARDEN CITY, N.Y., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) today announced that they have entered into a definitive agreement under which UNIVO Pharmaceutical Industries Ltd ("UNIVO") Univo Pharmaceutical Industries Ltd. ("UNIVO"), a public company whose shares are listed for trading on the Tel Aviv Stock Exchange (TASE:UNVO), will acquire control over the outstanding shares of NeuroNOS Israel Ltd. ("NeuroNOS"), a biopharmaceutical company focused on devel
- SECSEC Form EFFECT filed by Beyond Air Inc.EFFECT - Beyond Air, Inc. (0001641631) (Filer)
- SECSEC Form 424B3 filed by Beyond Air Inc.424B3 - Beyond Air, Inc. (0001641631) (Filer)
- SECBeyond Air Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Beyond Air, Inc. (0001641631) (Filer)
- SECSEC Form S-3 filed by Beyond Air Inc.S-3 - Beyond Air, Inc. (0001641631) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Beyond Air Inc.SCHEDULE 13G/A - Beyond Air, Inc. (0001641631) (Subject)
- SECSEC Form 10-Q filed by Beyond Air Inc.10-Q - Beyond Air, Inc. (0001641631) (Filer)
- PRBeyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate UpdateReports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 PMA supplement for second-generation LungFit PH system under FDA review; approval expected in 2H CY2026 Recent financing up to $30.1 million to support ongoing international expansion and U.S. commercial launch of second-generation LungFit PH system, pending regulatory approval Conference call today at 8:00 a.m. ET GARDEN CITY, N.Y., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (N
- SECSEC Form 8-K filed by Beyond Air Inc.8-K - Beyond Air, Inc. (0001641631) (Filer)
- PRBeyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026GARDEN CITY, N.Y., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that it will report financial results for its quarter ended June 30, 2026 on Thursday, August 13, 2026. The Company's management team is scheduled to host a conference call and webcast at 8:00 a.m. Eastern Time (ET) the same day. Conference Call & Webcast Thursday, August 13th @ 8 a.m. ET Domestic: 1-877-407-0784International: 1-201-689-8560Conference ID:13762077 Webcast: A webcast of the live conference call can be
- INSIDERChief Executive Officer Goodman Robert Scott bought $199,999 worth of shares (34,722 units at $5.76), increasing direct ownership by 34,722% to 34,822 units (SEC Form 4)4 - Beyond Air, Inc. (0001641631) (Issuer)
- INSIDERChief Financial Officer Moorhead Daniel J bought $24,998 worth of shares (4,340 units at $5.76) (SEC Form 4)4 - Beyond Air, Inc. (0001641631) (Issuer)
- SECBeyond Air Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Beyond Air, Inc. (0001641631) (Filer)
- PRBeyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq RulesGARDEN CITY, N.Y., July 30, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients’ lives, today announced that it has entered into a securities purchase agreement for the purchase and sale of (i) an aggregate of 167,011 shares of the Company’s common stock and accompanying warrants at a combined purchase price of $5.66 per share to certain institutional investors ("Purchase Price") and a combined purchase price of $5.76 per share to certain of the Company’s directors and officers, and (ii) in lieu of shares of common sto
- SECBeyond Air Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Beyond Air, Inc. (0001641631) (Filer)
- SECBeyond Air Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Beyond Air, Inc. (0001641631) (Filer)
XAIR FAQ
6 questionsWhat does Beyond Air Inc. do?
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of persistent pulmonary hypertension of the newborn; acute viral pneumonia, including COVID-19; bronchiolitis and nontuberculous mycobacteria lung infections; and solid tumors. It operates in Israel, Ireland, Australia, and the European Union. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond...Where does XAIR stock trade?
Beyond Air Inc. (XAIR) is listed on NASDAQ.What sector and industry is XAIR in?
Beyond Air Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about XAIR?
Beyond Air Inc. has had 6 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $1000.00 price target on 2026-09-01. Recent price targets range from $1000.00 to $1600.00.What companies are similar to XAIR?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare XAIR side-by-side with any of them on Quantisnow.How can I track XAIR on Quantisnow?
Quantisnow aggregates Beyond Air Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XAIR to receive live email and push alerts on every new disclosure.